Table 3. Results of meta-analysis of the association between rs1413711 polymorphism of VEGF-A gene and AMD risk.
| Genotype contrast | Na | Cases/Controls | OR (95% CI) |
Significance (Z test)b |
Heterogeneity(Q test) |
|||
|---|---|---|---|---|---|---|---|---|
| Z | P | Q | I2 (%) | P | ||||
|
overall |
4 |
554/551 |
||||||
| T versus C |
1.15 (0.86–1.56) |
0.98 |
0.32 |
7.96 |
62.3 |
0.04 |
||
| TT versus CC |
1.50 (0.71–3.16) |
1.07 |
0.28 |
10.51 |
71.5 |
0.01 |
||
| CT versus CC |
0.90 (0.69–1.18) |
0.72 |
0.47 |
5.72 |
47.6 |
0.12 |
||
| TT versus CT |
1.74 (1.22–2.48) |
3.09 |
0 |
3.96 |
24.2 |
0.26 |
||
| (CT+TT) versus CC |
0.98 (0.65–1.49) |
0.05 |
0.95 |
7.72 |
61.1 |
0.05 |
||
| TT versus (CC+CT) |
1.69 (0.98–2.89) |
1.92 |
0.05 |
6.63 |
54.8 |
0.08 |
||
| (CC+TT) versus CT |
1.23 (0.97–1.57) |
1.73 |
0.08 |
2.84 |
0 |
0.41 |
||
|
wet AMD |
4 |
414/551 |
||||||
| T versus C |
1.13 (0.83–1.54) |
0.8 |
0.42 |
7.32 |
59 |
0.06 |
||
| TT versus CC |
1.44 (0.68–3.05) |
0.95 |
0.34 |
9.5 |
68.4 |
0.02 |
||
| CT versus CC |
0.82 (0.54–1.26) |
0.87 |
0.38 |
6.12 |
51 |
0.1 |
||
| TT versus CT |
1.82 (1.22–2.71) |
2.97 |
0 |
2.51 |
0 |
0.47 |
||
| (CT+TT) versus CC |
0.94 (0.60–1.48) |
0.24 |
0.81 |
7.86 |
61.8 |
0.04 |
||
| TT versus (CC+CT) |
1.63 (1.13–2.35) |
2.66 |
0 |
5.24 |
42.7 |
0.15 |
||
| (CC+TT) versus CT | 1.25 (0.96–1.63) | 1.69 | 0.09 | 3.07 | 2.4 | 0.38 | ||
aNumber of studies. bRandom-effects model was used when p value for heterogeneity test p<0.1 or I2>50%; otherwise, fixed-effects model was used.